Drugs & Targets FDA clears IND for Zymeworks’ antibody drug conjugate ZW191 July 26, 2024Vol.50 No.30
Drugs & Targets EMA validates application for BMS’s Opdivo + Yervoy for unresectable or advanced HCC July 26, 2024Vol.50 No.30
Drugs & Targets FDA grants Fast Track designation to 225Ac-FL-020 radiopharmaceutical for mCRPC July 12, 2024Vol.50 No.28
Drugs & Targets Boehringer Ingelheim, OSE Immunotherapeutics collaborate to advance clinical development of SIRP immuno-oncology program July 12, 2024Vol.50 No.28
Drugs & Targets Wistar, Accelerated Biosciences collaborate to develop immune cell therapies July 12, 2024Vol.50 No.28
Drugs & Targets FDA grants Fast Track designation to Syncromune Inc. for drug-device combo for solid tumors in mCRPC July 05, 2024Vol.50 No.27
Drugs & Targets EMA CHMP adopts positive opinion for Tepkinly in R/R follicular lymphoma July 05, 2024Vol.50 No.27
Drugs & Targets EMA CHMP adopts positive opinion for odronextamab for R/R follicular lymphoma or R/R DLBCL July 05, 2024Vol.50 No.27
